Efficacy of iPSC-derived chimeric antigen receptor T cell therapy for cervical cancer

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07249
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Juntendo University
• Principal Investigator: Ando Jun 順天堂大学, 医学部, 教授 (60348943)
• Co-Investigator(Kenkyū-buntansha): 安藤 美樹 順天堂大学, 医学部, 教授 (10424251) ; 寺尾 泰久 順天堂大学, 医学部, 教授 (00348997)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: キメラ抗原受容体T細胞療法 / B7-H3 / 子宮頸がん / iPS細胞技術

Outline of Final Research Achievements

Cervical cancer is increasing in the young generation and with those found in the advanced stages, complete cure is difficult to achieve and therefore their prognosis is extremely poor. CD19-CART therapy for Acute lymphocytic leukemia (ALL) and lymphoma has already been successfully applied. CART therapy for solid tumor is also progressing, but there is still no promising CART therapy for cervical cancer. We confirmed that cervical cancer cell lines are strongly positive for B7-H3 (CD276). In this study, using the iPS cell technology that we have developed so far, we will conduct basic studies aimed at developing effective and powerful CART therapy targeting B7-H3 in cervical cancer cells.

Free Research Field

免疫細胞療法

Academic Significance and Societal Importance of the Research Achievements

子宮頸がんの限局期には手術や放射線治療、化学療法が選択されるが、進行期では根治が望めず極めて予後不良である。特に手術や放射線治療、化学療法後の再発・難治性の子宮頸がん患者には手立てがなく、新規治療開発が喫緊の課題である。われわれの開発するCART療法が新規治療につながる可能性があるので、学術的に重要な検討であり意義があると思われる。